Focuses on developing cell and exosome-based therapies for the treatment of cardiovascular and Duchenne muscular dystrophy.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company based in San Diego, California, is dedicated to advancing transformative cell and exosome-based therapies across a wide spectrum of diseases and disorders. The company's flagship candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, has completed a phase III clinical trial targeting patients with late-stage Duchenne muscular dystrophy (DMD). Additionally, CAP-1002 is currently undergoing phase II trials for the treatment of cytokine storm associated with SARS-CoV-2. Capricor is also progressing CAP-2003 through pre-clinical development aimed at addressing trauma-related injuries and conditions. Moreover, the company is actively developing two vaccine candidates designed to potentially prevent COVID-19 infections.
Capricor Therapeutics collaborates closely with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, underscoring its commitment to ensuring robust production capabilities for its cell therapy candidates. This strategic partnership reinforces Capricor's ability to scale its therapeutic offerings effectively. Founded in 2005, the company has established itself as a leader in leveraging innovative biotechnological approaches to address significant unmet medical needs.
With a strong emphasis on advancing cutting-edge therapies and vaccines, Capricor Therapeutics continues to expand its research and development efforts. The company's mission is anchored in pioneering treatments that have the potential to revolutionize healthcare outcomes, further solidifying its position at the forefront of the biotechnology industry.